NASDAQ: ENGNEngene Holdings Inc Stock
$14.72-0.03 (-0.2%)
Updated Apr 25, 2024
ENGN Price
$14.72
Fair Value Price
N/A
Market Cap
$641.52M
52 Week Low
$6.69
52 Week High
$47.17
P/E
N/A
P/B
10.28x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.5
Operating Cash Flow
N/A
Beta
-0.03
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ENGN Overview
Forbion European Acquisition Corp. is a "blank check" company formed to effect mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations. It targets the life sciences industry in Europe. Forbion European Acquisition was incorporated in 2021 and is based in Wilmington, DE.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ENGN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ENGN is poor value based on its book value relative to its share price (10.28x), compared to the US Biotechnology industry average (5.8x)
P/B vs Industry Valuation
ENGN's short-term assets ($89.58M) exceed its short-term liabilities ($6.91M)
Short-term Liabilities Financials
ENGN's short-term assets ($89.58M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more ENGN due diligence checks available for Premium users.
Be the first to know about important ENGN news, forecast changes, insider trades & much more!
ENGN News
Valuation
ENGN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
15.41x
Market
40.97x
ENGN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
10.28x
Industry
5.8x
ENGN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ENGN's financial health
Profit margin
Revenue
$0.0
Net Income
-$10.7M
Profit Margin
0%
Assets to liabilities
Assets
$93.4M
Liabilities
$31.0M
Debt to equity
0.5
ENGN's short-term assets ($89.58M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ENGN's short-term assets ($89.58M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ENGN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.4M
Investing
-$506.0k
Financing
$12.0M
ENGN vs Biotech Stocks
Engene Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.